Location History:
- San Diego, CA (US) (2007 - 2017)
- Potomac, MD (US) (2012 - 2023)
Company Filing History:
26 out of 26 
5 out of 5 
1 out of 1,327 
Years Active: 2007-2025
Title: Albert B. Deisseroth: Innovator in Cancer Therapy and Infectious Disease Reduction
Introduction
Albert B. Deisseroth, based in Potomac, MD, is a prolific inventor with 31 patents to his name. His work predominantly focuses on innovative therapies for cancer and the management of infectious diseases. His insights and inventions have contributed significantly to the fields of immunotherapy and infectious disease research.
Latest Patents
Among his latest contributions to science are two impactful patents. The first, titled "Combination Cancer Therapy," introduces a method for treating cancer patients using a combination of two distinct immunotherapy solutions. This method involves administering a checkpoint inhibitor antibody, such as a PD-1 or PD-L1 antibody, through infusion, alongside a TAA/ecdCD40L vaccine component administered subcutaneously. The key aspect lies in the sequential administration of both therapies, enhancing the therapeutic effect compared to administering either solution alone.
The second significant patent, "Burkholderia pseudomallei Composition," is a composition aimed at reducing the virulence of Burkholderia pseudomallei (Bp). This cDNA composition encodes fusion proteins that combine fragments of Bp proteins with a potent immunostimulatory protein, CD40 ligand. This innovative approach seeks to increase levels of neutralizing antibodies, thereby providing protection against lethal challenges posed by Bp.
Career Highlights
Deisseroth’s career includes impactful roles in companies like Microvax, LLC and Vaxum, LLC, where he has applied his expertise in biotechnology and immunotherapy. His extensive experience in these organizations underscores his commitment to advancing medical science through innovative solutions.
Collaborations
Throughout his career, Deisseroth has collaborated with prominent researchers and scientists, including Yucheng Tang and Lixin Zhang. These collaborations have fostered an environment of innovation and have led to significant advancements in several therapeutic areas.
Conclusion
Albert B. Deisseroth's contributions to the fields of cancer treatment and infectious disease management through his patents and collaborations highlight his role as a key innovator in the realm of biotechnology. His ongoing work continues to pave the way for new therapeutic approaches that offer hope for patients facing complex health challenges.